Assessment of Rebound in Cancer Diagnoses in California in 2022, by Stage, Sociodemographic Factors, and Rurality
Authors:
- Erin L. Van BlariganEBErin L. Van Blarigan
- Alison J. CancholaACAlison J. Canchola
- Li ZhuLZLi Zhu
- Salma Shariff-MarcoSSSalma Shariff-Marco
- Mindy C. DeRouenMDMindy C. DeRouen
- Iona ChengICIona Cheng
- Meg McKinleyMMMeg McKinley
- Debora L. OhDODebora L. Oh
- Katherine LinKLKatherine Lin
- Scarlett Lin GomezSGScarlett Lin Gomez
- 17 December 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (3) , 415-419
Abstract
Background: The reduction in cancer cases in 2020 has been attributed to missed diagnoses during the pandemic, yet no rebound occurred in 2021. We examined whether cancer rebounded in California in 2022. Methods: Data on invasive tumors in California for 2001 to 2022 were obtained through the NCI Surveillance, Epidemiology, and End Results program. Expected cases for 2022 were calculated using joinpoint regression models based on trends from 2001 to 2021 (omitting 2020). We calculated the ratio of observed to expected (O/E) cases in 2022 and 95% confidence intervals (CI). Results: There was no overall difference in observed versus expected invasive tumors in California in 2022. However, lung cancer was 29% lower than expected in rural areas (O/E: 0.71; 95% CI, 0.39–0.95), uterine cancer was lower than expected in Los Angeles (O/E: 0.91; 95% CI, 0.86–0.96), and breast cancer was lower than expected in Greater California (O/E: 0.95; 95% CI, 0.90–0.98). Groups with more tumors observed than expected included unstaged colorectal cancer in Greater California (O/E: 1.54) and Los Angeles (O/E: 1.26), colorectal cancer among males (O/E: 1.12) and Asian Americans (O/E: 1.16) in the Greater Bay Area, localized melanoma in Greater California (O/E: 1.24), and prostate cancer among Hispanic males in Los Angeles (O/E: 1.24). Conclusions: Overall, observed invasive tumors did not differ from expected in California in 2022, but there was variation across demographic, regional, and clinical factors. The reduction in cancer cases in 2020 likely reflects multiple factors, including missed diagnoses and death due to competing causes. Impact: Continued close monitoring of cancer diagnoses is needed to inform cancer control strategies.Keywords
All Related Versions
Funding Information
- National Institutes of Health
- Centers for Disease Control and Prevention
- California Department of Public Health
This publication has 18 references indexed in Scilit:
- Disparities in cancer incidence by rurality in CaliforniaJNCI: Journal of the National Cancer Institute, 2023
- Evaluation of the Impact of the COVID-19 Pandemic on Reliability of Cancer Surveillance Data in the National Cancer DatabaseAnnals of Surgical Oncology, 2022
- Association of the COVID-19 Pandemic With Rates of Prostate Cancer Biopsies and Diagnoses in Black vs White US VeteransJAMA Oncology, 2022
- Updated Methodology for Projecting U.S.- and State-Level Cancer Counts for the Current Calendar Year: Part II: Evaluation of Incidence and Mortality Projection MethodsCancer Epidemiology, Biomarkers & Prevention, 2021
- Association of the COVID-19 Pandemic With Patterns of Statewide Cancer ServicesJNCI: Journal of the National Cancer Institute, 2021
- Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American SeniorsJCO Clinical Cancer Informatics, 2020
- Effects of the COVID-19 Pandemic on Cancer-Related Patient EncountersJCO Clinical Cancer Informatics, 2020
- Patients With Lung Cancer Have High Susceptibility of COVID-19: A Retrospective Study in Wuhan, ChinaCancer Control, 2020
- Improved confidence interval for average annual percent change in trend analysisStatistics in Medicine, 2017
- Permutation tests for joinpoint regression with applications to cancer ratesStatistics in Medicine, 2000